Beyond Shingles: Shingrix Research Fuels Hope for Dementia Prevention

Growing interest in the shingles vaccine Shingrix is bringing renewed attention to research suggesting that vaccination may be associated with a lower risk of dementia. The emerging evidence has attracted scientists, healthcare professionals and members of the public searching for ways to protect cognitive health as populations age.

The findings have raised an important question for preventive medicine: could a vaccine developed to protect against a painful viral infection also offer benefits for the ageing brain?

Researchers have reported associations between shingles vaccination and reduced rates of dementia diagnosis in several studies. However, scientists have yet to establish conclusively whether Shingrix directly prevents dementia, delays its onset or produces other neurological benefits.

Read Also: Pharmacy Board Looks to Shape Future of Pharmaceutical Practice

The distinction matters because dementia remains a major public health challenge, affecting memory, reasoning, communication and independent living. Families frequently shoulder significant caregiving responsibilities, while healthcare systems must provide long-term support for people whose conditions progress.

Shingrix is already an established vaccine for preventing shingles and related complications. Its possible connection with dementia prevention has introduced a new dimension to its medical significance, although further evidence is needed before this potential benefit can be incorporated into routine clinical recommendations.

Shingles Vaccine Research Raises New Questions

Shingles, medically known as herpes zoster, occurs when the varicella-zoster virus that causes chickenpox becomes active again after remaining dormant in the body. The condition can cause a painful rash and, in some cases, persistent nerve pain known as postherpetic neuralgia.

Scientists have increasingly investigated whether infections and immune-system responses may influence the development of dementia. Some studies have explored whether viral activity, inflammation and changes in immune function could contribute to processes associated with cognitive decline.

These questions have prompted researchers to examine whether preventing shingles could have benefits extending beyond the prevention of infection itself.

A study published in Nature Medicine in July 2024 compared dementia outcomes among people receiving different shingles vaccines in the United States. Researchers examined health records involving more than 200,000 people and found that recipients of the newer recombinant vaccine experienced more time without a recorded dementia diagnosis than recipients of the older live-attenuated vaccine.

The researchers estimated approximately 164 additional dementia-diagnosis-free days among recipients of the newer vaccine over the study’s six-year observation period. The association appeared stronger among women than men.

The 2024 Nature Medicine study on shingles vaccination and dementia strengthened interest in whether newer vaccine formulations might have benefits beyond their primary purpose.

However, the study relied on observational health records rather than a randomised clinical trial specifically designed to test dementia prevention. Its findings therefore demonstrate an association, not definitive proof that the vaccine caused the difference.

New Findings Strengthen the Case for Further Investigation

Additional research has continued to build the scientific discussion surrounding shingles vaccination and brain health.

A study published in Nature Communications in February 2026 examined recombinant zoster vaccination among adults aged 65 and older in Southern California. The retrospective study included 65,800 vaccinated individuals and 263,200 matched unvaccinated individuals.

Read Also: Top Comoros Official Hospitalized in Nairobi Amid Rising Tensions in Moroni

Researchers reported that receiving two doses of the recombinant zoster vaccine was associated with a 51 per cent lower risk of dementia during the study’s follow-up period. The association remained when vaccinated individuals were compared with a group that had received a tetanus, diphtheria and pertussis vaccine, although the estimated difference was smaller.

The 2026 Nature Communications research on recombinant zoster vaccination adds to the evidence suggesting that the relationship deserves closer scientific examination.

The reported 51 per cent reduction should not be interpreted as a guarantee that vaccination will reduce an individual’s personal dementia risk by the same amount. Observational studies can account for many differences between groups, but they cannot eliminate every possible influence, including unmeasured health and lifestyle factors.

A separate study published in Nature in April 2025 investigated a shingles vaccination programme in Wales. Researchers used differences in vaccine eligibility based on date of birth to compare people who were similar in age but differed in their eligibility for vaccination.

Read Also: KNEC Grade 10 Assessment 2026: Guidelines, Timelines & School Requirements 

The study found that eligibility for the older live-attenuated vaccine was associated with an approximately 20 per cent relative reduction in new dementia diagnoses over seven years.

The Welsh shingles vaccination study published in Nature offered additional evidence because its research design helped reduce some of the biases that can affect conventional comparisons between vaccinated and unvaccinated populations.

Nevertheless, the Welsh study examined the older Zostavax vaccine rather than Shingrix. Its findings cannot automatically be transferred to the newer vaccine.

Together, the studies have strengthened the rationale for further research, but they have not established shingles vaccination as a proven dementia-prevention treatment.